tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

SpringWorks Therapeutics downgraded to Neutral from Outperform at Wedbush

Wedbush downgraded SpringWorks Therapeutics (SWTX) to Neutral from Outperform after Merck KGaA (MKGAY) and SpringWorks announced the companies have entered into a definitive agreement for Merck KGaA to acquire SpringWorks for $47 per share in cash.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1